Cell, gene, and other novel therapies require carefully designed and well executed logistics solutions for supplying lifesaving medicine to patients. Biological material sourced and produced for autologous and allogeneic therapies must be strictly controlled for temperature, timeline, as well as chain of identity and custody. This complexity was expanded by the COVID pandemic which has caused disruption in supply of materials, as well as manufacturing and logistics processes. On the other hand, smart technologies, digital solutions, and innovative operation models have driven the rapid evolution of global CGT clinical and commercial distribution. This session will explore the following topics: • Planning and ensuring manufacturing capacity to serve the patient/market need. • Solving supply chain challenges for clinical and/or commercial cell therapy products. • Case studies of digital solution (electronic system integration), smart technologies and operation model successfully applied in supply chain management.